09.08.11
CMC Biologics and Oxford BioTherapeutics (OBT) entered into a non-exclusive license agreement providing OBT with access to CMC Biologics' CHEF1 expression system for R&D and commercial use. CMC's CHEF1 cell line development platform is designed to promote high-level expression of recombinant proteins early in development to allow for rapid isolation of cell lines. OBT plans to use the CHEF1 system for the production of its oncologic therapeutic antibodies. Financial terms were not disclosed
"We are very pleased to add CMC Biologics' CHEF1 system to our technology portfolio. Access to the best expression systems is critical for our antibody development team, helping us accelerate production and development of our most promising anticancer agents," said Tom Boone, who recently joined OBT as senior vice president, Protein Sciences, following 28 years at Amgen.
"CMC Biologics is delighted to provide its CHEF1 expression system to OBT," said Mads Laustsen, chief scientific officer of CMC Biologics. "We believe the advantages of the CHEF1 system will help OBT generate cell lines in a highly efficient and effective way."
"We are very pleased to add CMC Biologics' CHEF1 system to our technology portfolio. Access to the best expression systems is critical for our antibody development team, helping us accelerate production and development of our most promising anticancer agents," said Tom Boone, who recently joined OBT as senior vice president, Protein Sciences, following 28 years at Amgen.
"CMC Biologics is delighted to provide its CHEF1 expression system to OBT," said Mads Laustsen, chief scientific officer of CMC Biologics. "We believe the advantages of the CHEF1 system will help OBT generate cell lines in a highly efficient and effective way."